Guest Blog: Stigma and fear of cancer
June 17, 2014 · Comments Off
Two years ago, Celia, now retired, had a cough that didn’t seem to go away. A lung x-ray at a routine physical showed a “milky way” image. After going through numerous tests, she eventually received the diagnosis: Stage 4 non-small cell lung cancer. Without treatment, the doctor told her she had only eight months to live. It was something she thought only happened to other people.
Tumor Responses with Crizotinib in MET-Amplified Disease Help Define a New Targetable Form of Lung Cancer
June 2, 2014 · Comments Off
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
With early and obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
August 8, 2013 · Comments Off
When a drug's benefit is obvious in a clinical trial's first or second phase, is the third, costly phase needed? The question is posed in a recent edition of the journal Nature Reviews: Clinical Oncology by Robert C. Doebele, MD, PhD, investigator at the University of Colorado Cancer Center and assistant professor of medical oncology at the CU School of Medicine.
Lung cancer patients developing areas of drug-resistance prolong disease control by using focused radiation to weed the garden
November 28, 2012 · Comments Off
KEY POINTS: Pockets of cancer may mutate to gain resistance to targeted therapies It’s possible...
Changing the face of lung cancer
July 19, 2012 · Comments Off
His goal is changing the face of lung cancer. Former NFL linebacker Chris Draft is...
New combo lung cancer therapy improves survival over single-line treatment
December 14, 2010 · Comments Off
University of Colorado-developed treatment effective in Phase 2 Trials in a biomarker-selected group of patients...
Bitter melon juice prevents pancreatic cancer in mouse models
December 14, 2010
NTRK1: a new oncogene and target in lung cancer
December 14, 2010
amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer clinical trials cancer grants cancer prevention cancer research colorado Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
Have you liked us on FB yet? If not, be sure to do so for the latest updates on research, clinical trials, and events on.fb.me/1BRkDDh